Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals says several patients have been enrolled in two Phase I studies of its cancer drug candidate.
Subscribe to our email newsletter
The studies of PEG-SN38, Enzon’s pegylated form of SN38, the active metabolite of the cancer drug Camptosar, are designed to evaluate the safety, tolerability, and pharmacokinetics of the drug in different dosing schedules for patients with advanced solid tumors or lymphoma.
At the April 2007 American Association for Cancer Research annual meeting, researchers presented positive preclinical data for PEG-SN38. The data showed that treatment with the pegylated SN38 resulted in significant tumor growth inhibition in mice resistant to Camptosar and outperformed Camptosar in mice when given as a second round therapy. Additionally, PEG-SN38 demonstrated long-lasting antitumor activity in mouse models of human breast, colorectal and pancreatic cancers.
“The positive preclinical data showing tumor growth inhibition in Camptosar-resistant mice generated a lot of excitement around this product candidate in the oncology field,” claims Jeffrey Buchalter, Enzon’s chairman and CEO. “Resistant tumors are very difficult to treat. We look forward to evaluating PEG-SN38 in patients with cancer and hope to develop a product that can help these people.”